Manufacturer
MALAYSIAN PHARMACEUTICAL INDUSTRIES SDN. BHD.
Contents
Clobetasol 17-propionate
Indication
Corticosteroid-responsive dermatoses.
Instruction
Apply thinly and rub gently onto the affected area once daily or bid, reduced if necessary. Max dose: 50 g wkly. Max duration of therapy: 4 wk.
Drug interaction
Increased systemic exposure w/ CYP3A4 enzyme inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplstic effect of aldesleukin. May potentiate the hyperglycaemic effect of ceritinib. May diminish the therapeutic effect of corticorelin and hyaluronidase. May enhance the adverse/toxic effects of deferasinox.
Malaysia
